ArticleMaterials today. Bio2026
High-throughput microfluidics and machine learning-assisted screening of lipid nanoparticle formulations for siRNA delivery.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles (LNPs) are among the most advanced non-viral carriers for RNA delivery; however, the optimization of LNP formulations remains challenging due to the vast and multi-dimensional formulation space. Here, we established a high-throughput microfluidic and machine learning-assisted workflow for stepwise LNP formulation prioritization for siRNA delivery. A library of 864 candidate formulations was generated, and 203 randomly selected empty LNPs were experimentally characterized. Machine learning models were then used to predict particle size and PDI across the full formulation library, supporting the selection of 25 candidates for siRNA loading and biological validation. The results showed that the size have positive relationship with lipids concentration, and the PEG ratio have negative relationship with size, and positive with PDI. After siRNA loading, all selected formulations-maintained particle sizes below 150 nm. In vitro gene silencing results showed that SM-102- and CKK-E12-based formulations achieved stronger S100P knockdown, with relative S100P expression levels reduced to 0.0744 and 0.0611, respectively. In vivo biodistribution analysis further showed that CKK-E12-based LNPs exhibited higher lung signals compared with the other three ionizable lipid groups. These results indicate that favorable physicochemical properties are necessary but not sufficient to ensure optimal biological performance, highlighting the importance of biological validation after model-assisted screening. Overall, this workflow provides a practical strategy for integrating high-throughput formulation preparation, model-assisted prioritization, and biological validation for siRNA-LNP development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.